ArticleCell cycle (Georgetown, Tex.)2015
Fasting protects against the side effects of irinotecan but preserves its anti-tumor effect in Apc15lox mutant mice.
Article in Cell cycle (Georgetown, Tex.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 42 citations in OpenAlex.
- Effect of Short-Term Fasting on Systemic Cytochrome P450-Mediated Drug Metabolism in Healthy Subjects: A Randomized, Controlled, Crossover Study Using a Cocktail Approach.Clinical pharmacokinetics · 2017Trial
- The role of the microbiota in hematological malignancies: A narrative review of mechanisms and therapeutic potential.New microbes and new infections · 2026Review
- Effect of short-term fasting on the cisplatin activity in human oral squamous cell carcinoma cell line HN5 and chemotherapy side effects.BMC cancer · 2024Article
- Mechanisms driving fasting-induced protection from genotoxic injury in the small intestine.American journal of physiology. Gastrointestinal and liver physiology · 2024Article
- Impact of Caloric Restriction in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Prospective Case Control Study.Nutrients · 2023Article
- Fasting: From Physiology to Pathology.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- Short-term fasting and fasting mimicking diets combined with chemotherapy: a narrative review.Therapeutic advances in medical oncology · 2023Review
- Fatty acids homeostasis during fasting predicts protection from chemotherapy toxicity.Nature communications · 2022Article
- Fasting and fasting-mimicking diets for chemotherapy augmentation.GeroScience · 2021Review
- How Far Are We from Prescribing Fasting as Anticancer Medicine?International journal of molecular sciences · 2020Review
- Article
- Effects of short-term fasting on cancer treatment.Journal of experimental & clinical cancer research : CR · 2019Review
- The transcriptomic response to irinotecan in colon carcinoma bearing mice preconditioned by fasting.Oncotarget · 2019Article
- Caloric restriction is associated with preservation of muscle strength in experimental cancer cachexia.Aging · 2018Article
- Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics.Clinical pharmacokinetics · 2018Review
- Protective effects of short-term dietary restriction in surgical stress and chemotherapy.Ageing research reviews · 2017Review
- Gut microbiota modulation of chemotherapy efficacy and toxicity.Nature reviews. Gastroenterology & hepatology · 2017Review
- Fasting protects against the side effects of irinotecan treatment but does not affect anti-tumour activity in mice.British journal of pharmacology · 2016Article
- Ramadan Fasting and Patients with Cancer: State-of-the-Art and Future Prospects.Frontiers in oncology · 2016Review
- Not so fast: dietary restriction improves chemotherapy-related toxicity.Cell cycle (Georgetown, Tex.) · 2015Article
Corrections and comments
- Commented on by
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Irinotecan is a widely used topoisomerase-I-inhibitor with a very narrow therapeutic window because of its severe toxicity. In the current study we have examined the effects of fasting prior to irinotecan treatment on toxicity and anti-tumor activity. FabplCre;Apc(15lox/+) mice, which spontaneously develop intestinal tumors, of 27 weeks of age were randomized into 3-day fasted and ad libitum fed groups, followed by treatment with a flat-fixed high dose of irinotecan or vehicle. Side-effects were recorded until 11 days after the start of the experiment. Tumor size, and markers for cell-cycle activity, proliferation, angiogenesis, and senescence were measured. Fasted mice were protected against the side-effects of irinotecan treatment. Ad libitum fed mice developed visible signs of discomfort including weight loss, lower activity, ruffled coat, hunched-back posture, diarrhea, and leukopenia. Irinotecan reduced tumor size in fasted and ad libitum fed groups similarly compared to untreated controls (2.4 ± 0.67 mm and 2.4 ± 0.82 mm versus 3.0 ± 1.05 mm and 2.8 ± 1.08 mm respectively, P < 0.001). Immunohistochemical analysis showed reduced proliferation, a reduced number of vascular endothelial cells, and increased levels of senescence in tumors of both irinotecan treated groups. In conclusion, 3 days of fasting protects against the toxic side-effects of irinotecan in a clinically relevant mouse model of spontaneously developing colorectal cancer without affecting its anti-tumor activity. These results support fasting as a powerful way to improve treatment of colorectal carcinoma patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.